Skip to main content
SpringerLink
Log in

Chemotherapy in Non-Small Cell Lung Cancer

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1998, CA Cancer J Clin 48: 6–29, 1998

    Google Scholar 

  2. Friese G, Gabler A, Lieberg S: Bronchial carcinoma and long term survival. Thorax 33: 228–234, 1978

    Google Scholar 

  3. Vogl SE, Berenzweig M, Camacho F, Greenwald E, Kaplan BH: Efficacy study of intensive cis-platin therapy in advanced non-small cell bronchogenic carcinoma. Cancer 50: 24–26, 1982

    Google Scholar 

  4. Samson MK, Comis RL, Baker LH, Ginsberg S, Fraile RJ, Crooke ST: Mitomycin C in advanced carcinoma and large cell carcinoma of the lung. Cancer Treat Rep 62: 163–165, 1978

    Google Scholar 

  5. Harrison EF, Hawke JE, Hunter HL, Costanzi JJ, Morgan LR, Plotkin D, Tucker WG, Worrall PM: Single-dose ifosfamide: efficacy studies in non-small cell lung cancer. Semin Oncol 9: 56–60, 1982

    Google Scholar 

  6. Furnas, BE, Williams SD, Einhom LH, Cobleigh MA: Vindesine: an effective agent in the treatment of non-small cell lung cancer. Cancer Treat Rep 66: 1709–11, 1982

    Google Scholar 

  7. Schulman P, Budman DR, Vinciguerra V, Weiselberg L, Abrams S and Degnan T: Phase II study of divided-dose vinblastine in non-small cell bronchogenic carcinoma. Cancer Treat Rep 66: 171–172, 1982

    Google Scholar 

  8. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Cornis R et al.: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV nonsmall-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7: 1602–1613, 1989

    Google Scholar 

  9. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss R. A, Vogl S: A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 4: 14–22, 1986

    Google Scholar 

  10. Einhorn LH, Loehrer, PJ, Williams SD, Meyers S, Gabrys T, Nattan, SR, Woodburn, R, Drasga R, Songer J, Fisher W et al.: Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol 4: 1037–1043, 1986

    Google Scholar 

  11. Klastersky J, Sculier JP, Ravez P, Libert P, Michel J, Vandermoten G, Rocmans P, Bonduelle, Y, Mairesse, M, Michiels, T et al.: A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol 4: 1780–1786, 1986

    Google Scholar 

  12. Buccheri G, Ferrigno D: A randomised trial of MACC chemotherapy with or without lonidamine in advanced nonsmall cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG), [see comments]. Eur J Cancer 10: 1424–1431, 1994

    Google Scholar 

  13. Crino L, Clerici M, Figoli F, Carlini P, Ceci G, Cortesi E, Carpi A, Santini A, Di Costanzo F, Boni C et al.: Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol 6: 347–353, 1995

    Google Scholar 

  14. Klastersky J, Sculier JP, Bureau G, Libert P, Ravez P, Vandermoten G, Thiriaux J, Lecomte J, Cordier R, Dabouis G, et al.: Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium. J Clin Oncol 7: 1087–1092, 1989

    Google Scholar 

  15. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg SM et al.: Evaluation of cisplatin intensity in metastatic nonsmall-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 11: 873–878, 1993

    Google Scholar 

  16. Longeval E, Klastersky J: Combination chemotherapy with cisplatin and etoposide in bronchogenic; squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium). Cancer 50: 2751–2756, 1982

    Google Scholar 

  17. Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J et al.: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 0786 1. J Clin Oncol 8: 1556–1562, 1990

    Google Scholar 

  18. Albain KS, Crowley JJ, LeBlanc M, Livingston RB: Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9: 1618–1626, 1991

    Google Scholar 

  19. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P et al.: Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 13: 1221–1230, 1995

    Google Scholar 

  20. Jiroutek M, Johnson D, Blum R, Bonomi, P, Ruckdeschel J, Schiller J, Sandler A: Prognostic factors in advanced non-small cell lung cancer (NSCLC): Analysis of Eastern Cooperative Oncology Group Trials from 1981–1992. Proc Am Soc Clin Oncol 17: 461 (abstr), 1998

    Google Scholar 

  21. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM et al.: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 6: 633–641, 1988

    Google Scholar 

  22. Jaakkimainen L, Goodwin PJ, Pater J, Warde P, Murray N, Rapp E: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 8: 1301–1309, 1990

    Google Scholar 

  23. Cartei G, Cartei F, Cantone A, Causarano D, Genco G, Tobaldin A, Interlandi G, Giraldi T: Cisplatincyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer, [see comments], J Natl Cancer Inst 85: 794–800, 1993

    Google Scholar 

  24. Woods RL, Williams CJ, Levi J, Page J, Bell D, Byrne M, Kerestes ZL: A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 61: 608–611, 1990

    Google Scholar 

  25. Cellerino R, Tummarello D, Guidi F, Isidori P, Raspugli M, Biscottini B, Fatati G: A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 9: 1453–1461, 1991

    Google Scholar 

  26. Stewart LA, Pignon JP: Non Small Cell Lung Cancer Collaborative group, Chemotherapy in non-small cell lung cancer. Meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311: 899–907, 1995

    Google Scholar 

  27. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F: Chemotherapy vs supportive care in advanced non-small cell lung cancer. Results of a meta-analysis of the literature, [see comments], Chest 106: 861–865, 1994

    Google Scholar 

  28. Mason B, Catalano RB: Mitomycin, vinblastine and cisplatin combination chemotherapy in non-small cell lung cancer. Proc Am Assoc Clin Oncol A477, 1980

  29. Eagan RT, Ingle JN, Frytak S, Rubin J, Kvols LK, Carr DT, Coles DT, O'Fallon JR: Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer. Cancer Treat Rep 61: 1339–1345, 1977

    Google Scholar 

  30. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277: 665–667, 1979

    Google Scholar 

  31. Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys, 22, 613–617, 1992

    Google Scholar 

  32. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D: Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results, [see comments]. J Natl Cancer Inst 85: 388–394, 1993

    Google Scholar 

  33. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN et al.: Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer, [see comments], J Natl Cancer Inst 85: 384–388, 1993

    Google Scholar 

  34. Gatzemeier U, Heckmayer M, Neuhauss R, Schluter I, von Pawel J, Wagner H, Dreps A: Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial. Semin Oncol 22: 24–28, 1995

    Google Scholar 

  35. Millward MJ, Bishop JF, Friedlander M, Levi JA, Goldstein D, Olver LN, Smith JG, Toner GC, Rischin D, Bell DR: Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 14: 142–148, 1996

    Google Scholar 

  36. Ringel I, Horwitz SB: Studies with RP56976 (Taxotere): a semi-synthetic analogue of taxol. J Mad Cancer Inst 83: 288–291, 1991

    Google Scholar 

  37. Lira-Puerto V, Zepeda G, Mohar A, Gallardo D, de la Garza J, Silva A, Palma F, Martinez R, Erazo A, Cervantes G, Torrecillas L, Morgan G, Gerson R, Figuero J, Moyaho I, Aguilar C, Fuentas H, Burbano G, Aguilar J: Phase II trial of (Taxotere) docetaxel in advanced non small cell lung cancer. Proc Am Soc Clin Oncol 14: 382 (abstract), 1995

    Google Scholar 

  38. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T: Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol 14: 1649–1655, 1996

    Google Scholar 

  39. Miller VA, Rigas JR, Francis PA, Grant SC, Pisters KM, Venkatraman ES, Woolley K, Heelan RT, Kris MG: Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75: 968–972, 1995

    Google Scholar 

  40. Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chasen M, Shin DM, Glisson B, Benner S et al., Phase II study of docetaxel for recurrent or metastatic nonsmall-cell lung cancer, J Clin Oncol, 12, 1238–1244, 1994

    Google Scholar 

  41. Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, Heelan RT: Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 12: 1238–1244, 1994

    Google Scholar 

  42. Cerny T, Kaplan S, Pavlidis N, Schoffski P, Epelbaurn R, van Meerbeek J, Wanders J, Franklin HR, Kaye S: Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG), [see comments]. Br J Cancer 70: 384–387, 1994

    Google Scholar 

  43. Burris H, Eckardt J, Fields S: Phase II trial of taxotere in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 12: 335 (abstract), 1993

    Google Scholar 

  44. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W: Pharmacologically directed design of the dose rate and schedule of 20,20-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 50: 6823–6826, 1990

    Google Scholar 

  45. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH: Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1821–1826, 1994

    Google Scholar 

  46. Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJ, Rosso R, Mattson K, Cortes-Funes H, Tonato M, Burkes RL, Gottfried M, Voi M: Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 32A: 243–248, 1996

    Google Scholar 

  47. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1535–1540, 1994

    Google Scholar 

  48. Anderson H, Cottier B, Nicolson M et al.: Phase III Study of Gemcitabine versus Best Supportive Care in Advanced Non-Small Cell Lung Cancer. Lung Cancer 18 (suppl 1): 9, 1997

    Google Scholar 

  49. Perng RP, Chen YM, Ming-Liu J, Tsai CM, Lin WC, Yang KY, Whang Peng J: Gemcitabine versus the Combination of Cisplatin and Etoposide in Patients with Inoperable Non-Small Cell Lung Cancer in a Phase II Randomized Study. J Clin Oncol 15: 2097–2102, 1997

    Google Scholar 

  50. Manegold C, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen P, Liippo K, Mattson K, van Pawel J, Ricci S, Sederholm C, Stahel RA, Wagenius G, van Walree N, ten Bokkel-Huinink W: Single-Agent Gemcitabine versus Cisplatin-Etoposide: Early results of a Randomised Phase II Study in Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Ann Oncol 8: 525–529, 1997

    Google Scholar 

  51. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH: The current status of camptothecin analogues as antitumor agents, J Natl Cancer Inst 85: 271–291, 1993

    Google Scholar 

  52. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N et al.: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer, [see comments], J Clin Oncol 10: 16–20, 1992

    Google Scholar 

  53. Negoro S, Fukuoka M, Niitani H, Suzuki A, Nakabayashi T, Kimura M, Motomiya M, Kurita Y, Hasegawa K, Kuriyama T et al.: A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group. Gan To Kagaku Ryoho 18: 1013–1019, 1991

    Google Scholar 

  54. Baker L, Khan R, Lynch T, Savaraj N, Sandler A, Feun L, Schaser R, Hanover C. Phase II study of irinotecan in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 16: 1658 (abstract), 1997

    Google Scholar 

  55. Douillard JY, Ibrahim N, Riviere A, Spaeth D, Chomy P, Soussan K, Mathieu-Boue A: Phase II study of CPT-11 (irinotecan) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14: 365 (abstract), 1995

    Google Scholar 

  56. Cvitkovic E, Izzo J: The current and future place of vinorelbine in cancer therapy. Drugs 44: 36–45; discussion 66–69, 1992

    Google Scholar 

  57. Crawford J, O'Rourke M, Schiller JH, Spiridonidis CH, Yanovich S, Ozer H, Langleben A, Hutchins L, Koletsky A, Clamon G, Burman S, White R, Hohneker J, Spiridonitis CH: Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer, [see comments], published effatum appears in J Clin Oncol 1996 Dec; 14(12):3175. J Clin Oncol 14: 2774–2784, 1996

    Google Scholar 

  58. Depierre A, Lemarie E, Dabouis G, Gamier G, Jacoulet P, Dalphin JC: A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 14: 1159, 1991

    Google Scholar 

  59. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S et al.: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients, [see comments]. J Clin Oncol 12: 360–367, 1994

    Google Scholar 

  60. Gridelli C, Perrone F, Gallo C: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91: 66–72, 1999

    Google Scholar 

  61. Schabel FM, Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr: cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63: 1459–1473, 1979

    Google Scholar 

  62. Parker RJ, Dabholkar MD, Lee KB, Bostick-Bruton F, Reed E: Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst Monogr 15: 83–88, 1993

    Google Scholar 

  63. Jekunen AP, Christen RD, Shalinsky DR, Howell SB: Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 69: 299–306, 1994

    Google Scholar 

  64. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE et al: Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9: 1692–1703, 1991

    Google Scholar 

  65. LeBlanc GA, Sundseth SS, Weber GF, Waxman DJ: Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res 52: 540–547, 1992

    Google Scholar 

  66. Klastersky J, Sculier JP: Cisplatin plus taxol in non-small cell lung cancer. Proc Am Assoc Cancer Res 36: 1423 (abstract), 1995

    Google Scholar 

  67. Belli L, LeChevalier T, Gottfried M, Adams D, Ruffie P, LeCesne A, Tete L, Pellae-Cosset B: Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced nonsmall cell lung cancer: preliminary results. Semin Oncol 22: 29–33, 1995

    Google Scholar 

  68. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Comblath DR, Donehower RC: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is doselimiting. J Clin Oncol 11: 2010–2020, 1993

    Google Scholar 

  69. Pirker R, Krajnik G, Zochbauer S, Malayeri R, Kneussl M, Huber H, Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 6: 833–835, 1995

    Google Scholar 

  70. Bonomi PD, Kim KD, Chang A et al.: Phase III trial comparing etoposide (E) cisplatin versus Taxol with cisplatin-G-CSF (G) versus cisplatin?? in advanced non-small cell lung cancer: Eastern Cooperative Oncology Group (ECOG), Proc Am Soc Clin Oncol, 15, 382 (abstract), 1996

    Google Scholar 

  71. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Ozols RF: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 13: 1860–1870, 1995

    Google Scholar 

  72. Belani CP, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, Engstrom C, Ramanathan RK, Capozzoli MJ, Aisner J, Egorin MJ: Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 17: 676–684, 1999

    Google Scholar 

  73. Bunn PA Jr, Kelly K: A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol 22: 2–6, 1995

    Google Scholar 

  74. Johnson DH, Paul DM, Hande KR, DeVore R: Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN 46). Semin Oncol 23: 42–46, 1996

    Google Scholar 

  75. Roa V, Conner A, Mitchell RB: Carboplatin and paclitaxel for chemotherapy naive patients with advanced non-small cell lung cancer. Proc Am Assoc Clin Oncol 15: 404 (abstract), 1996

    Google Scholar 

  76. Rowinsky EK, Flood WA, Sartorius SE, Bowling MK, Wagner J, Ettinger DS: Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Semin Oncol 22: 48–54, 1995

    Google Scholar 

  77. Giaccone G, Huizing M, Postmus PE, ten Bokkel Huinink WW, Koolen M, van Zandwijk N, Vermorken JB, Beijnen JH, Dalesio O, Pinedo HM et al.: Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer. Semin Oncol 22: 78–82, 1995

    Google Scholar 

  78. Belani CP, Natale JS, Lee M, Socinski M, Waterhouse D, Rowland K, Ansari R, Lilenbaurn R, Sridhar K: Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/ paclitaxel in advanced and metastatic non-small cell lung cancer. Proc Am Assoc Clin Oncol 17: 455 (abstract), 1998

    Google Scholar 

  79. Giaccone G, Splinter TA, Debruyne C, Kho GS, Lianes P, van Zandwijk N, Permucci MC, Scagliotti G, van Meerbeeck J, van Hoesel Q, Curran D, Sahmoud T, Postmus PE: Randomized study of paclitaxel-cisplatin versus cisplatin-eniposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 16: 2133–2141, 1998

    Google Scholar 

  80. Gatzemeier U, von Pawel J, Gottfried M, ten Velde GPM, Mattson K, DeMarinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Winograd B, Gallant G: Phase III comparative trial of high does cisplatin (HD-CIS) versus combination of paclitaxel and cisplatin (CIS) in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17: 454 (abstract), 1998

    Google Scholar 

  81. Zalcberg J, Millward M, Bishop J, McKeage M, Zimet A, Toner G, Friedlander M, Barter C, Rischin D, Loret C, James R, Bougan N, Berille J: Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol 16: 1948–1953, 1998

    Google Scholar 

  82. Le Chevalier T, Mormier A, Douillard JY, Ruffle P, Sun XS, Belli L, Ibrahim N, Bougon N, Berille J: Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur J Cancer 34: 2032–2036, 1998

    Google Scholar 

  83. Cole JT, Gralla RJ, Marques CB, Rittenberg CN: Phase III study of cisplatin + docetaxel (Taxotere) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14: 357 (abstract), 1995

    Google Scholar 

  84. Gebbia V, Caruso M, Valenza R, Testa A, Cannata G, Verderame F, Cipolla C, Curto G, Oliveri D, Chiarenza M: Vinorelbine plus cisplatinurn for the treatment of stage IIIB and IV non small cell lung carcinoma. Anticancer Res 14: 1247–1249, 1994

    Google Scholar 

  85. Berthaud P, Le Chevalier T, Ruffie P, Baldeyrou P, Arriagada R, Besson F, Tursz T: Phase I-II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer 11: 1863–1865, 1992

    Google Scholar 

  86. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB: Randomized trial comparing cisplatin with cisplatin plus navelbine in the treatment of advanced non-small cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 16: 2459–2465, 1998

    Google Scholar 

  87. Santomaggio C, Tucci E, Rinaldini M, Algeri R, Righi R, Pepi F, Ghezzi P, Andrei A, Bellezza A: Carboplatin and vinorelbine in the treatment of advanced non-small-cell lung cancer: a multicenter phase II study. Am J Clin Oncol 21: 67–71, 1998

    Google Scholar 

  88. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22: 72–79, 1995

    Google Scholar 

  89. Peters GJ, Ruiz van Haperen VW, Bergman AM, Veerman G, Smitskamp-Wilms E, van Moorsel CJ, Kuiper CM, Braakhuis BJ: Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 23: 16–24, 1996

    Google Scholar 

  90. Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, Salvati F, Cruciani G, Dogliotti L, Pucci F, Paccagnella A, Adarno V, Altavilla G, Incoronato P, Trippetti M, Mosconi AM, Santucci A, Sorbolini S, Oliva C, Tonato M: Cisplatin-gemcitabine in combination in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 15: 297–303, 1997

    Google Scholar 

  91. Sandler, AB, Ansari, R, McClean, J, Einhorn, L.H, A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small cell lung cancer. Cancer Therapeutics. 1: 158–163, 1998

    Google Scholar 

  92. Anton A, Diaz-Fernandez N, Gonzalez Larriba JL, Vadell C, Masutti B, Montalar J, Barneto L, Artal A, Rosell R: Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC). Lung Cancer 22: 139–148, 1998

    Google Scholar 

  93. Steward WP: Combination studies with gemcitabine in the treatment of non-small-cell lung cancer. Br J Cancer 78: 15–19, 1998

    Google Scholar 

  94. Green MR, Eisenberg P, Kosty M, Stolbach J, Hainsworth J, Zaknoen S: Activity and tolerability of Gemcitabine plus Weekly Cisplatin in Advanced Non-Small Cell Lung Cancer. Proc Amer Soc Clin Oncol 17: 468 (abstr), 1998

    Google Scholar 

  95. Shepherd FA, Cormier Y, Burkes R, Evans WK, Goss G, Klimo P, Feld R, Taylor M: Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Semin Oncol 24: S8–27–S8–30, 1997

    Google Scholar 

  96. Abratt RP, Sandler A, Crino L, Steward WP, Shepherd FA, Green MR, Nguyen B, Peters GJ: Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. Semin Oncol 25: 35–43, 1998

    Google Scholar 

  97. Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, Garcia M, Lianes P, Montalar J, Vadell C, Gonzalez-Larriba JL, Nguyen B, Artal A, Rosell R: Randomized phase III study of gemcitabinecisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer patients. J Clin Oncol 17: 12–18, 1999

    Google Scholar 

  98. Sandler A, Nemunatis J, Delmm C, von Pawel J, Niyikiza C, Cormier Y, Nguyen B, Einhorn L: Phase III study of cisplatin with or without gemcitabine in patients with advanced nonsmall cell lung cancer. J Clin Oncol (submitted), 1999

  99. Crino L, Conte P, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Matano A, Marangolo M, Bartolucci R, Oliva C, Tonato M: A randomized trial of gemitabine, cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer. A multicenter phase III study. Proc Am Soc Clin Oncol 17: 455 (abstract), 1998

    Google Scholar 

  100. Carmichael J, Allerheilgen S, Walling J: A phase I/II study of gemcitabine and carboplatin in NSCLC. Proc Am Soc Clin Oncol 14: 351 (abstract), 1995

    Google Scholar 

  101. Ng EW, Sandler AB, Einborn LH: Phase II study of carboplatin plus gemcitabine in nonsmall cell lung cancer (NSCLC). Amer J Clin Oncol (accepted for publication), 1999

  102. Iaffaioli RV, Tortoriello A, Facchini G, Caponigro F, Gentile M, Marzano N, Gravina A, Dimitri P, Costagliola G, Ferraro A, Ferrante G, De Marino V, Illiano A: Phase I-II Study of Gemcitabine and Carboplatin in Stage IIIB-IV Non-Small-Cell Lung Cancer. J Clin Oncol 17: 921–926;, 1999

    Google Scholar 

  103. Martinez J, Panizo A, Alonso MA, Munoz J, De Cos Sanchez J, Sampedro JR, Hernandez J: Gemcitabine Plus Carboplatin in Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase I Trial. Proc Am Soc Clin Oncol 17: 494 (abstract), 1998

    Google Scholar 

  104. Devore R 3rd, Johnson D, Crawford J, Dimery L, Eckardt J, Eckhardt SG: Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. Oncology (Huntingt) 12: 79–83, 1998

    Google Scholar 

  105. Masuda N, Fukuoka M, Fujita A, Kurita Y, Tsuchiya S, Nagao K, Negoro S, Nishikawa H, Katakami N, Nakagawa K, Niitani H: A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group, [see comments]. Br J Cancer 78: 251–256, 1998

    Google Scholar 

  106. Nakagawa K, Fukuoka M, Kudoh S: Phase II study of irinotecan (CPT-11) and cisplatin in patients with advanced NSCLC. Proc Am Soc Clin Oncol 12: 332 (abstract), 1993

    Google Scholar 

  107. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K, Kishimoto S: CPT-11 in combination with cisplatin for advanced nonsmall cell lung cancer. J Clin Oncol 10: 1775–1780, 1992

    Google Scholar 

  108. Jagasia M, Langer C, Yunis F, Rogers J, Lamar R, Schlabach L, Johnson D, Krozely P, McCullough N, Shyr Y, Carbone D, DeVore R: Preliminary result of a multicenter phase II trial of weekly cisplatin (CDDP) and irinotecan (CPT-11) in patients with advanced non-small cell lung cancer (NSCLC): A Vanderbilt Cancer Center Affiliate Network Study. Proc Am Soc Clin Oncol 18: 510 (abstr), 1999

    Google Scholar 

  109. Masuda N, Fukuoka M, Negoro S, Takada Y, Sugiura T, Ohashi Y, Arioshi Y, Nitani H: Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phasee III trial. Proc Am Soc Clin Oncol 18: 459 (abstract), 1999

    Google Scholar 

  110. Niho S, Nagao K, Nishiwaki A, Yokoyama A, Saijo N, Ohashi Y, Niitani H: Randomized phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 18: 492 (abstr), 1999

    Google Scholar 

  111. Dorie MJ, Brown JM: Tumor specific, schedule-dependent interaction between tirapazarnine (SR 4233) and cisplatin. Cancer Res 53: 4633–4636, 1993

    Google Scholar 

  112. Treat J, Johnson E, Langer C, Belani C, Haynes B, Greenberg R, Rodriquez R, Drobins P, Miller W Jr, Meehan L, McKeon A, Devin J, von Roemeling R, Viallet J: Tirapazarnine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 16: 3524–3527, 1998

    Google Scholar 

  113. Rodriquez GJ, Valdivieso M, von Hoff DD: A phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small-cell lung cancer. Proc Am Soc Clin Oncol 15: 1144 (abstract), 1996

    Google Scholar 

  114. Miller VA, Ng KK, Grant SC, Kindler H, Pizzo B, Heelan RT, von Roemeling R, Kris MG: Phase II study of the novel bioreductive agent, tirapazamine with cisplatin in patients with dvanced non-small-cell lung cancer. Ann Oncol 8: 1269–1271, 1997

    Google Scholar 

  115. von Pawel J, von Roemeling R: Survival benefit from tirapazamine and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: final results from the international phase III CATAPULT I Trial. Proc Am Soc Clin Oncol 17: 454 (abstract), 1998

    Google Scholar 

  116. Kelly K, Crowley J, Bunn PA, Livingston RB, Gandara DR: A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorlebine plus cisplatin (VC) in untreated advanced nonsmall cell lung cancer (NSCLC): A southwest Oncology Group (SWOG) Trial. Proc Am Soc Clin Oncol 18: 461 (abstract), 1999

    Google Scholar 

  117. Georgoulias V, Androulakis N, Kouroussis Ch et al.: Second-Line Treatment with Paclitaxel (P) and Gemcitabine (G) in Patients with Non-Small Cell Lung Cancer (NSCLC) Who Failed CisplatinBased Chemotherapy. Proc Amer Soc Clin One 17: 468 (abstract), 1998

    Google Scholar 

  118. Giaccone G, Smit E, Laan D, Splinter T, van Meerbeek J, Postmus P: Phase I/II Study of Paclitaxel and Gemcitabine in Advanced Non-Small Cell Lung Cancer (NSCLC). Proc Am Soc Clin Oncol 17: 486 (abstract), 1998

    Google Scholar 

  119. Garland LL, Wagner H, Shaw GS, Williams CC, Antonia SA, Khoor LM, Muelemans LM, Nimmons KA, Ruckdeschel JC: Phase I Dose-Escalation Study of Constant Rate Infusion Gemcitabine in Combination with Taxotere in Advanced Non-Small Cell Lung Cancer. Proc Amer Soc Clin One 17: 484 (abstr), 1998

    Google Scholar 

  120. Spiridonidis CH, Laufman LR, Jones J, Rhodes VA, Wallace K, Nicol S: Phase I Study of Docetaxel Dose Escalation in Combination with Fixed Weekly Gemcitabine in patients with Advanced Malignancies. J Clin Oncol 16: 3866–3873, 1998

    Google Scholar 

  121. Schlosser NJJ, Richel DJ, Van Zandwijk N, Kroeze MA, Middel RPG, Schoot M: Phase I Study of Docetaxel and Gemcitabine Combination Chemotherapy in Chemotherapy Naive Patients with Advanced or Metastatic Non Small Cell Lung Cancer. Proc Am Soc Clin Oncol 17: 499 (abstract), 1998

    Google Scholar 

  122. Georgoulias V, Kouroussis Ch, Androulakis N, Kakolyris AM, Dirnopoulos E, Papadakis E, Papadimitrou Ch, Hatzakis K, Bania E, Apostolopoulou F, Tsiafaki X, Alexopoulos A, Souglakos J, Kotsakis Th, Vlachonicolis J, Hatzidaki D: Front-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Docetaxel (D) and Gemcitabine (G): A Multicenter Phase II Trial. Proc Amer Soc Clin Onc 17: 473 (abstract), 1998

    Google Scholar 

  123. Esteban E, Llano JL, Vieitez JM, Fra J, Puertas J, Estrada E, Palacio I, Muniz JM, Buesa JM, Lacave AJ: Phase I/II Study of Gemcitabine Plus Vinorelbine in Non-Small Cell Lung Cancer (NSCLC). Proc Am Soc Clin Oncol 17: 482 (abstract), 1998

    Google Scholar 

  124. Lilenbaum RC, Schwartz MA, Cano R, Krill E, Lutzky J, Blaustein A, Seigel M, Viales M, Dominguez CJ, Davila E: Gemcitabine (GEM) and Navelbine (NVB) in Advanced NonSmall Cell Lung Cancer (NSCLC), Proc Am Soc Clin Oncol, 17, 494 (abstract), 1998

    Google Scholar 

  125. Lorusso V, Mancarella S, Carpagnano F, Rienzo, Cisternino, Napoli G, Orlando S, Cinieri S, Brunetti C, Palazzo S, Catino A, Paradiso N, Panza De Cataldis G, Frasci G, De Lano M: Gemcitabine Plus Vinorelbine in Patients with Stage IIIB-IV Non Small Cell Lung Cancer (NSCLC). A Phase II Study. Proc Am Soc Clin Oncol 17: 470 (abstract), 1998

    Google Scholar 

  126. Herbst RS, Khuri FR, Jung FV, Fossella FV, Lee JS, Glisson B, Shin DM, Pisters K, Papadimtrakopoulou V, Kurie J, Perez-Soler R, Liu D, Munden K, Hong WK: Phase II Study of Combination Weekly Gemcitabine and Vinorelbine in Patients with untreated or previously treated non-small cell lung cancer. Proc Amer Soc Clin Onc 18: 462 (abstract), 1999

    Google Scholar 

  127. Isokangas 0P, Mattson K, Joensuu H, Tamminen K, Nikkanen V, Viren M, Brisgand D, Barbet I: A Phase II Study of Vinorelbine (VNR) and Gemcitabine (GEM) in Inoperable Stage IIIB-IV NSCLC. Proc Amer Soc Clin Onc 17: 489 (abstract), 1998

    Google Scholar 

  128. Rocha Lima CM, Perkel JA, Putman-Hair, Sherman CA, Leong SS, Green MR: Ongoing Phase I Study of Irinotecan and Gemcitabine. Proc Am Soc Clin Oncol 17: 250 (abstract), 1998

    Google Scholar 

  129. Kourousis C, Androulakis N, Kakolyris S, Souglakos J, Maltezakis G, Metaxaris G, Chalkiadakis G, Samonis G, Vlachonikolis J, Georgoulias V: First-line treatment of advanced non-small cell lung carcinoma with docetaxel and vinorelbine. Cancer 83: 2083–2090, 1998

    Google Scholar 

  130. Krug LM, Kris MG, Grant SC, NG KK, Heelan RT, Pizzo BA, Perez W, Miller VA: Phase II trial of dose dense docetaxel plus vinorelbine with prophylactic filgrastim (GCSF) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 18: 460 (abstr), 1999

    Google Scholar 

  131. Hainsworth JD, Erland JB, Kalman LA, Hon JK, Smith SW, Greco FA: Phase I/II Trial of Paclitaxel, (I-Hour Infusion), Carboplatin, and Gemcitabine in the Treatment of Advanced Non-Small Cell Lung Cancer. Proc Amer Soc Clin Onc 17: 471 (abstract), 1998

    Google Scholar 

  132. Kelly K, Prindiville S, Bunn PA, Jr: A Phase I Trial of Paclitaxel (P), Carboplatin (C), and Gemcitabine (G) in Advanced Non-Small Cell Lung Cancer (NSCLC): A University of Colorado Cancer Center Study. Proc Amer Soc Clin One 17: 490 (abstract), 1998

    Google Scholar 

  133. Frasci G, Comella P, Panza N, Pacilio C, Nicolella GP, Natale M, Manzione L, Gravina A, Cioffi R, Maiorina L, Comella G: Cisplatin-Gemcitabine-Paclitaxel in Advanced NonSmall Cell Lung Cancer (NSCLC). A Dose-Finding Study. Proc Amer Soc Clin Onc 17: 481 (abstract), 1998

    Google Scholar 

  134. Sorensen JB, Stenbyggard LE, Hansen HH, Dombernowsky P: Biweekly Paclitaxel, Gemcitabine, and Cisplatin in Non-Resectable Non-Small Cell Lung Cancer (NSCLC), Proc Amer Soc Clin Onc 17: 501 (abstract), 1998

    Google Scholar 

  135. Gonzalez-Baron M, Garcia MJ, Chacon JI, Ordonez A, Madronal C, Murias A, Cruz MA, de Castro J, Feliu J, Colmenarejo A, Aguiar J: A Phase II Study of Gemcitabine, Cisplatin and Vinorelbine in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Proc Amer Soc Clin Onc 17: 469 (abstract), 1998

    Google Scholar 

  136. Dorta J, Martin G, Constenla M, Lizon J, Leon A, Cruz JJ, Lorenzo I, Gonzalez-Baron M, Garcia Puche JL: A Phase II Study of Gemcitabine, Cisplatin and Vinorelbine in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Proc Amer Soc Clin Onc 17: 482 (abstract), 1998

    Google Scholar 

  137. Castellano D, Lianes P, Calzas J, Garcia-Carbonera R, Guerra JA, Gomez H, Cortes-Funes H: Non-Cisplatin-Based Chemotherapy for Advanced Non Small Cell Lung Cancer (NSCLC): A Phase II Study with Gemcitabine (G), Ifosfamide (I) and Vinorelbine (N). Proc Amer Soc Clin Onc 17: 480 (abstract), 1998

    Google Scholar 

  138. Gralla RJ, Rittenberg CR, Silverman CR, Marques CB, Maulick JF: Gemcitabine (G) + Vinorelbine (V) in combination with mitomycin (M) in non small cell lung cancer (NSCLC). Results of a phase I and II study of an active outpatient regimen. Proc Am Soc Clin Oncol 17: 486 (abstract), 1998

    Google Scholar 

  139. Boni C, Bisagni G, Savoldi L, Franciosi V, Pezzola A, De Pas T: Gemcitabine, Ifosfamide, Cisplatin (GIP) for the Treatment of Stage IIIB-IV Non Small Cell Lung Cancer (NSCLC). A Phase II Study of the Italian Oncology Group for Clinical Research. Proc Amer Soc Clin Onc 17: 478 (abstract), 1998

    Google Scholar 

  140. Rey F, Astoul P, Marqueste L, Petite JM, Boutin C, Viallat JR: Cisplatin, ifosfamide, and vinorelbine combination chemotherapy in stage III-IV non-small-cell lung cancer: a phase II study. Am J Clin Oncol 21: 518–522, 1998

    Google Scholar 

  141. Miller LL, Socinski MA, Sandler AB, Hanover CK, Locker GE, Elfring GE, Israel VK, Natale RB: Phase I/II trial of paclitaxel (P), carboplatin (C), and irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 18: 475 (abstr), 1999

    Google Scholar 

  142. Le Chevalier T, Gatineau M, Daniel C, Rixe 0, Pailler MC, Fizaza K, Fontaine H, Rey A, Ruffle P: Phase II study of the combination of vinorelbine, cisplatin and tirapazamine in advance non-small cell lung cancer. Proc Am Soc Clin Oncol 18: 491 (abstr), 1999

    Google Scholar 

  143. Grimaldi M, Hainsworth JD, Butts JA, Morrissey LH, Erland JB, Litchey S, Burris HA, Greco FA: Paclitaxel, carboplatin and vinorelbine in the treatment of advance non-small cell lung cancer: A phase II trial of the Minnie Pearl Cancer Research Network. Proc Am Soc Clin Oncol 18: 507 (abstr), 1999

    Google Scholar 

  144. Georgoulias V, Androulakis N, Bouros D, Kouroussis C, Chatzakis K, Papadakis M, Apostopoloulou F, Georgopoulou T, Kotsakis T, Souklakos J, Hatzidaki D, Vlachonikolis J, Panagos G: Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: a multicenter phase II study of the Greek Cooperative Group for Lung Cancer. Lung Cancer 21: 213–220, 1998

    Google Scholar 

  145. Masters GA, Mauer AM, Hoffman PC, Wyka D, Samuels BL, Krauss SA, Watson S, Golomb H, Vokes EE: A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer. Ann Oncol 9: 677–680, 1998

    Google Scholar 

  146. Hainsworth JD, Thompson DS, Greco FA: Paclitaxel by I hour infusion. An active drug in metastatic non-small cell lung cancer. J Clin Oncol 13: 1609–1614, 1995

    Google Scholar 

  147. Ruckdeschel J, Wagner H Jr, Williams C, Hiese M, Hilstro J: Second-line chemotherapy for resistant, metastatic non-small cell lung cancer (NSCLC): The role of Taxol. Proc Am Soc Clin Oncol 13: 357 (abstract), 1994

    Google Scholar 

  148. Santoro A, Maiorino L, Santoro M: Second line therapy with vinorelbine in the weekly monochemotherapy for the treatment of advanced non small cell lung cancer. Lung cancer 11: 130 abstract (suppl 1), 1994

    Google Scholar 

  149. Niitani H, Fukuoka M, Furuse K: Clinical development of irinotecan (CPT-11) in lung cancers. Lung Cancer 11(suppl 2): 30–31, 1994

    Google Scholar 

  150. Crino L, De Marinis S, Darwish S. et al.: Salvage therapy with gemcitabine (GEM) in pretreated, advanced non-small cell lung cancer (NSCLC). Proc AmSoc Clin Oncol 16: 1603 (abstract), 1997

    Google Scholar 

  151. Fossella FV, DeVore R, Kerr R, Crawford R, Natale R, Dunphy F, Kalman L, Gandara D, Ganiza F, Hammershairrib Y, Kim Y, Crist W: Phase III trial of docetaxel 100 mg/m2 or 75 mg/m2 vs vinorelbine/ifosfamide for non-small cell lung cancer (NSCLC) previously treated with platinum based cehmotherapy (PBC). Proc Am Soc Clin Oncol 18: 460 (abstract), 1999

    Google Scholar 

  152. Shepherd F, Ramlau R, Mattson K, Gressot M, O'Rourke M, Vincent M, Burkes R, Levitan N, Bergman B, Kraszko P, Baez L, Lynch T, Rudd R, Berille J, Kim Y, Coughlin S, Gralla R: Randomized study of Taxotere (TAX) versus best supportive care (BSC) in non-small lung cancer (NSCLC) patients previously treated with platinum based chemotherapy. Proc Am Soc Clin Oncol 18: 463 (abstract), 1999

    Google Scholar 

  153. Crino L, Clerici M, Figoli F, Barduagni M, Carlini P, Ceci G, Cortesi E, Carpi A, Santini A, Di Costanzo F: Superiority of three-drug combination chemotherapy versus cisplatinetoposide in advanced non-small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research. Lung Cancer 12 Suppl 1: S125-S132, 1995

    Google Scholar 

  154. Steward WP, Dunlop C, Cameron DC et al.: Phase I/II study of cisplatin in combination with gemcitabine in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14: 1064 (abstract), 1995

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Indiana University Medical Center, Indianapolis, IN, USA

    Christopher J. Sweeney & Alan B. Sandler

Authors
  1. Christopher J. Sweeney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan B. Sandler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sweeney, C.J., Sandler, A.B. Chemotherapy in Non-Small Cell Lung Cancer. Invest New Drugs 18, 157–186 (2000). https://doi.org/10.1023/A:1006330030333

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006330030333

Search

Navigation